Corcept Faces Class Action Lawsuit Over Misleading FDA Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy CORT?
Source: Globenewswire
- Lawsuit Background: Hagens Berman has filed a class action lawsuit against Corcept Therapeutics, alleging that the company misled investors between October 2024 and December 2025, resulting in significant shareholder losses.
- Concealed FDA Warnings: The lawsuit claims that Corcept ignored multiple warnings from the FDA regarding inadequate clinical data before submitting its NDA, misleading investors about the drug's approval prospects.
- Stock Price Plummet: On December 31, 2025, Corcept received a Complete Response Letter from the FDA, causing its stock to drop from $70.20 to $34.80, erasing over $3.6 billion in market value and reflecting a sharp decline in market trust.
- Investor Action Call: Hagens Berman urges investors who purchased Corcept stock during the class period to contact them by April 21, 2026, to discuss becoming lead plaintiffs and protecting their rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 33.990
Low
50.00
Averages
91.00
High
121.00
Current: 33.990
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Faces Class Action Lawsuit Over Misleading Statements
- Lawsuit Background: Hagens Berman has filed a class action lawsuit against Corcept Therapeutics and its executives, alleging misleading statements made to investors between October 31, 2024, and December 30, 2025, resulting in significant investor losses.
- Concealed FDA Warnings: The lawsuit claims that Corcept misrepresented the regulatory viability of its lead product, relacorilant, despite multiple warnings from the FDA regarding inadequate clinical data, which misled investors about the drug's approval prospects.
- Stock Price Plunge: On December 31, 2025, Corcept's stock plummeted from $70.20 to $34.80 following the receipt of a Complete Response Letter from the FDA, erasing over $3.6 billion in market value, indicating a severe market reaction to the company's disclosures.
- Investor Rights Protection: Hagens Berman urges investors who purchased CORT stock during the class period to contact the firm by April 21, 2026, to discuss their rights and potential recovery of losses, emphasizing the importance of protecting investor interests in light of the allegations.
See More
Kyndryl and Others Face Class Action Lawsuits
- Kyndryl Lawsuit Overview: Kyndryl Holdings, Inc. (NYSE:KD) faces a class action lawsuit for materially misstated financial statements during the period from August 7, 2024, to February 9, 2026, with a lead plaintiff deadline of April 13, 2026, potentially impacting the company's reputation and stock volatility.
- PayPal Legal Issues: PayPal Holdings, Inc. (NASDAQ:PYPL) is accused in a class action lawsuit from February 25, 2025, to February 2, 2026, of failing to effectively execute its branded checkout initiatives, with a lead plaintiff deadline of April 20, 2026, which could affect its market competitiveness and investor confidence.
- NuScale Risk Disclosure: NuScale Power Corporation (NYSE:SMR) faces legal challenges in a class action lawsuit from May 13, 2025, to November 6, 2025, for not disclosing risks associated with its partnership with ENTRA1, with a lead plaintiff deadline of April 20, 2026, potentially hindering its commercialization strategy.
- Corcept Regulatory Challenges: Corcept Therapeutics Incorporated (NASDAQ:CORT) is involved in a class action lawsuit from October 31, 2024, to January 30, 2026, due to FDA concerns regarding the adequacy of its drug effectiveness assessment, with a lead plaintiff deadline of April 21, 2026, which may impact its drug approval process and company outlook.
See More
Corcept Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 31, 2024, and December 30, 2025, with a deadline to contact the firm by April 21, 2026.
- False Statements Allegation: The complaint alleges that Corcept made false and misleading statements regarding the viability of its product candidate, relacorilant, claiming it was 'approaching approval' while knowing that the FDA deemed its clinical data inadequate, resulting in investor losses when the truth emerged.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations, encouraging affected shareholders to reach out to discuss their rights and participate in the lawsuit, demonstrating the firm's commitment to protecting investor interests.
- Lawsuit Not Certified: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, highlighting the importance of taking action to avoid being an absent class member.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Litigation Timeline: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors can join the class action without any upfront fees or costs, as the law firm operates on a contingency fee basis, which alleviates the financial burden on investors seeking justice.
- Lawsuit Background: The lawsuit claims that throughout the class period, Corcept misrepresented the strength of clinical trials supporting its relacorilant NDA, while the FDA had raised concerns about the adequacy of evidence, exposing investors to potential losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked first by ISS in 2017, which underscores its expertise and successful track record in this legal domain.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Litigation Deadline: Investors are reminded that the lead plaintiff deadline for the Corcept Therapeutics (NASDAQ: CORT) class action is April 21, 2026, and those who purchased shares between October 31, 2024, and December 30, 2025, may be entitled to compensation.
- No Out-of-Pocket Costs: Participants in the class action can receive compensation without any upfront fees through a contingency fee arrangement, which alleviates financial burdens and encourages broader participation among investors.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, showcasing its extensive experience and success in this field, thereby enhancing investor confidence.
- FDA Approval Risks: The lawsuit alleges that Corcept misrepresented the adequacy of clinical trials for relacorilant's NDA, leading to significant investor losses when the truth emerged, highlighting potential misconduct in the company's information disclosure practices.
See More
Corcept Faces Lawsuit for Ignoring FDA Warnings, Stock Plummets 50%
- Lawsuit Background: Hagens Berman has filed a securities class action lawsuit against Corcept Therapeutics, alleging that the company misled investors between October 2024 and December 2025, resulting in a 50% drop in stock price.
- FDA Warnings: The lawsuit claims that while Corcept asserted its lead product candidate, relacorilant, was backed by 'powerful evidence' and nearing approval, the FDA had repeatedly warned that its clinical data was inadequate, which management allegedly ignored.
- Regulatory Compliance Issues: Under the Securities Exchange Act of 1934, Corcept is accused of making false and/or misleading statements, particularly as they proceeded with the NDA filing despite FDA's warnings of 'significant review issues', severely undermining investor confidence.
- Investor Rights Protection: Investors must apply to be lead plaintiffs by April 21, 2026, to protect their rights and seek compensation for losses, with Hagens Berman encouraging affected investors to reach out for more information.
See More
Corcept Therapeutics Faces Class Action Lawsuit Over Misleading Statements
- Lawsuit Background: Hagens Berman has filed a class action lawsuit against Corcept Therapeutics and its executives, alleging misleading statements made to investors between October 31, 2024, and December 30, 2025, resulting in significant investor losses.
- Concealed FDA Warnings: The lawsuit claims that Corcept misrepresented the regulatory viability of its lead product, relacorilant, despite multiple warnings from the FDA regarding inadequate clinical data, which misled investors about the drug's approval prospects.
- Stock Price Plunge: On December 31, 2025, Corcept's stock plummeted from $70.20 to $34.80 following the receipt of a Complete Response Letter from the FDA, erasing over $3.6 billion in market value, indicating a severe market reaction to the company's disclosures.
- Investor Rights Protection: Hagens Berman urges investors who purchased CORT stock during the class period to contact the firm by April 21, 2026, to discuss their rights and potential recovery of losses, emphasizing the importance of protecting investor interests in light of the allegations.
See More
Kyndryl and Others Face Class Action Lawsuits
- Kyndryl Lawsuit Overview: Kyndryl Holdings, Inc. (NYSE:KD) faces a class action lawsuit for materially misstated financial statements during the period from August 7, 2024, to February 9, 2026, with a lead plaintiff deadline of April 13, 2026, potentially impacting the company's reputation and stock volatility.
- PayPal Legal Issues: PayPal Holdings, Inc. (NASDAQ:PYPL) is accused in a class action lawsuit from February 25, 2025, to February 2, 2026, of failing to effectively execute its branded checkout initiatives, with a lead plaintiff deadline of April 20, 2026, which could affect its market competitiveness and investor confidence.
- NuScale Risk Disclosure: NuScale Power Corporation (NYSE:SMR) faces legal challenges in a class action lawsuit from May 13, 2025, to November 6, 2025, for not disclosing risks associated with its partnership with ENTRA1, with a lead plaintiff deadline of April 20, 2026, potentially hindering its commercialization strategy.
- Corcept Regulatory Challenges: Corcept Therapeutics Incorporated (NASDAQ:CORT) is involved in a class action lawsuit from October 31, 2024, to January 30, 2026, due to FDA concerns regarding the adequacy of its drug effectiveness assessment, with a lead plaintiff deadline of April 21, 2026, which may impact its drug approval process and company outlook.
See More
Corcept Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 31, 2024, and December 30, 2025, with a deadline to contact the firm by April 21, 2026.
- False Statements Allegation: The complaint alleges that Corcept made false and misleading statements regarding the viability of its product candidate, relacorilant, claiming it was 'approaching approval' while knowing that the FDA deemed its clinical data inadequate, resulting in investor losses when the truth emerged.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations, encouraging affected shareholders to reach out to discuss their rights and participate in the lawsuit, demonstrating the firm's commitment to protecting investor interests.
- Lawsuit Not Certified: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, highlighting the importance of taking action to avoid being an absent class member.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Litigation Timeline: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors can join the class action without any upfront fees or costs, as the law firm operates on a contingency fee basis, which alleviates the financial burden on investors seeking justice.
- Lawsuit Background: The lawsuit claims that throughout the class period, Corcept misrepresented the strength of clinical trials supporting its relacorilant NDA, while the FDA had raised concerns about the adequacy of evidence, exposing investors to potential losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked first by ISS in 2017, which underscores its expertise and successful track record in this legal domain.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Litigation Deadline: Investors are reminded that the lead plaintiff deadline for the Corcept Therapeutics (NASDAQ: CORT) class action is April 21, 2026, and those who purchased shares between October 31, 2024, and December 30, 2025, may be entitled to compensation.
- No Out-of-Pocket Costs: Participants in the class action can receive compensation without any upfront fees through a contingency fee arrangement, which alleviates financial burdens and encourages broader participation among investors.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, showcasing its extensive experience and success in this field, thereby enhancing investor confidence.
- FDA Approval Risks: The lawsuit alleges that Corcept misrepresented the adequacy of clinical trials for relacorilant's NDA, leading to significant investor losses when the truth emerged, highlighting potential misconduct in the company's information disclosure practices.
See More
Corcept Faces Lawsuit for Ignoring FDA Warnings, Stock Plummets 50%
- Lawsuit Background: Hagens Berman has filed a securities class action lawsuit against Corcept Therapeutics, alleging that the company misled investors between October 2024 and December 2025, resulting in a 50% drop in stock price.
- FDA Warnings: The lawsuit claims that while Corcept asserted its lead product candidate, relacorilant, was backed by 'powerful evidence' and nearing approval, the FDA had repeatedly warned that its clinical data was inadequate, which management allegedly ignored.
- Regulatory Compliance Issues: Under the Securities Exchange Act of 1934, Corcept is accused of making false and/or misleading statements, particularly as they proceeded with the NDA filing despite FDA's warnings of 'significant review issues', severely undermining investor confidence.
- Investor Rights Protection: Investors must apply to be lead plaintiffs by April 21, 2026, to protect their rights and seek compensation for losses, with Hagens Berman encouraging affected investors to reach out for more information.
See More
